45PCost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer
45PCost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer
Auteur
Blank, P.R.. European Center of Pharmaceutical Medicine (ECPM), University of Basel Institute of Pharmaceutical Medicine, Basel, Switzerland
Loibl, S.. Medicine and Research, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany
Linderholm, B.K.. Department of Oncology/Pathology, Karolinska University Hospital and Karolinska Institute-Huddinge, Stockholm, Sweden
Caramuta, S.. Department of Oncology/Pathology, Karolinska University Hospital and Karolinska Institute-Huddinge, Stockholm, Sweden
Nekljudova, V.. Medicine and Research, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany
Szucs, T.D.. European Center of Pharmaceutical Medicine (ECPM), University of Basel Institute of Pharmaceutical Medicine, Basel, Switzerland
Van Stiphout, J.. European Center of Pharmaceutical Medicine (ECPM), University of Basel Institute of Pharmaceutical Medicine, Basel, Switzerland
Ademi, Z.. European Center of Pharmaceutical Medicine (ECPM), University of Basel Institute of Pharmaceutical Medicine, Basel, Switzerland
von Minckwitz, G.. Medicine and Research, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany
Schwenkglenks, M.. European Center of Pharmaceutical Medicine (ECPM), University of Basel Institute of Pharmaceutical Medicine, Basel, Switzerland
Type de document
Postprint
Langue
Inglese
Publié dans
Annals of Oncology, 2015, vol. 26, p. iii16-iii17. Oxford University Press
